Overview
INCY market data
Price History
INCY price chart
Valuation & Profitability
- P/E (TTM)
- 15.34 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.41 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.73 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 27.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $78.20 – $132.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $24.7B · P/B 3.75 · P/S 4.25.
Company News
Mizuho Maintains Outperform on Incyte, Raises Price Target to $137Benzinga · Aug 4, 2026, 6:12 PM
Live On CNBC, Josh Brown Host Segment Titled “Josh’s Best Stocks In the Market: Incyte; Biogen"Benzinga · Aug 4, 2026, 4:36 PM
Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Aug 3, 2026, 12:16 PM
Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155Benzinga · Aug 3, 2026, 10:42 AM
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price TargetBenzinga · Aug 3, 2026, 10:18 AM
Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine YearsBenzinga · Aug 3, 2026, 6:36 AM
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109Benzinga · Jul 29, 2026, 5:34 PM
Incyte Analysts Raise Their Forecasts After Upbeat Q2 ResultsBenzinga · Jul 29, 2026, 2:52 PM
Guggenheim Maintains Buy on Incyte, Raises Price Target to $150Benzinga · Jul 29, 2026, 2:20 PM
BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130Benzinga · Jul 29, 2026, 1:55 PM